- Home
- Publications
- Publication Search
- Publication Details
Title
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume 38, Issue 7, Pages 3674-3693
Publisher
Springer Science and Business Media LLC
Online
2021-06-09
DOI
10.1007/s12325-021-01796-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer
- (2021) Sara S. Fois et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer
- (2021) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials
- (2021) Roger Olofsson Bagge et al. MELANOMA RESEARCH
- Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
- (2021) Anjali Rohatgi et al. Frontiers in Oncology
- Small cell lung cancer: a slightly less orphan disease after immunotherapy
- (2021) J. Remon et al. ANNALS OF ONCOLOGY
- ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer
- (2020) D. Planchard et al. ANNALS OF ONCOLOGY
- Immune checkpoint blockade in combination with stereotactic body radiotherapy in patients with metastatic pancreatic ductal adenocarcinoma
- (2020) Changqing Xie et al. CLINICAL CANCER RESEARCH
- A Phase IB study of Durvalumab with or without Tremelimumab and Platinum-Doublet Chemotherapy in Advanced Solid Tumours: Canadian Cancer Trials Group Study IND226
- (2020) Rosalyn A. Juergens et al. LUNG CANCER
- Landscape of transcriptome variations uncovering known and novel driver events in colorectal carcinoma
- (2020) Giovanna Pira et al. Scientific Reports
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
- (2020) R.L. Ferris et al. ANNALS OF ONCOLOGY
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16 ‐07
- (2020) Miso Kim et al. Thoracic Cancer
- Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
- (2020) Alice Boilève et al. EUROPEAN JOURNAL OF CANCER
- Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
- (2020) Jonathan W Goldman et al. LANCET ONCOLOGY
- A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract
- (2020) Michal Sarfaty et al. Cancer Medicine
- Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
- (2020) Suchita Pakkala et al. Journal for ImmunoTherapy of Cancer
- Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma
- (2019) Houda Bahig et al. BMC CANCER
- Efficacy and safety of nivolumab for metastatic biliary tract cancer
- (2019) Miaomiao Gou et al. OncoTargets and Therapy
- Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
- (2019) Maria Maddalena Simile et al. Medicina-Lithuania
- Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
- (2019) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
- (2019) Richard D. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab in cancer medicine: a comprehensive review
- (2019) Juliana Alvarez-Argote et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
- (2019) Osama M. Alshari et al. OncoTargets and Therapy
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Integrated Analysis of miRNA and mRNA Endorses a Twenty miRNAs Signature for Colorectal Carcinoma
- (2019) Andrea Angius et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
- (2019) et al. JAMA Oncology
- Multiple Signatures of the JC Polyomavirus in Paired Normal and Altered Colorectal Mucosa Indicate a Link with Human Colorectal Cancer, but Not with Cancer Progression
- (2019) Elena Uleri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Durvalumab for the treatment of non-small cell lung cancer
- (2019) Shuji Murakami Expert Review of Anticancer Therapy
- FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma
- (2018) Mashaal Dhir et al. ANNALS OF SURGICAL ONCOLOGY
- Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab
- (2018) Carlo Putzu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor
- (2018) Antonio Fadda et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma
- (2018) Jiyun Lee et al. LUNG CANCER
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
- (2018) Luana Calabrò et al. Lancet Respiratory Medicine
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis
- (2018) Andrea Necchi et al. EUROPEAN UROLOGY
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection
- (2018) Martin C. S. Wong et al. Scientific Reports
- Update on the current revolution in cancer immunotherapy
- (2018) Ariana Nicole Renrick et al. Immunotherapy
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
- (2018) Lillian L. Siu et al. JAMA Oncology
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
- (2017) Michiru Nishita et al. Scientific Reports
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
- (2016) Elizabeth D Thompson et al. GUT
- Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- (2016) Scott Antonia et al. LANCET ONCOLOGY
- Epidemiology of pancreatic cancer
- (2016) Milena Ilic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors
- (2015) Z. Cierna et al. ANNALS OF ONCOLOGY
- Frequent PD-L1 expression in testicular germ cell tumors
- (2015) C D Fankhauser et al. BRITISH JOURNAL OF CANCER
- Global Cancer Incidence and Mortality Rates and Trends--An Update
- (2015) L. A. Torre et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- 525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
- (2015) Y.J. Bang et al. EUROPEAN JOURNAL OF CANCER
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
- (2014) Luana Calabrò et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- Therapeutic use of anti-CTLA-4 antibodies
- (2014) C. U. Blank et al. INTERNATIONAL IMMUNOLOGY
- KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
- (2014) PANAGIOTIS PALIOGIANNIS et al. Oncology Letters
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
- (2012) C. Badoual et al. CANCER RESEARCH
- Epidemiology and Risk Factors of Urothelial Bladder Cancer
- (2012) Maximilian Burger et al. EUROPEAN UROLOGY
- Epidemiology and Risk Factors for Gastroesophageal Junction Tumors: Understanding the Rising Incidence of This Disease
- (2012) Matthew F. Buas et al. SEMINARS IN RADIATION ONCOLOGY
- Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis
- (2012) Sai Yendamuri et al. SURGERY
- Oligometastases revisited
- (2011) Ralph R. Weichselbaum et al. Nature Reviews Clinical Oncology
- Optimal treatment for recurrent/metastatic head and neck cancer
- (2010) J. B. Vermorken et al. ANNALS OF ONCOLOGY
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer
- (2010) Ki Y. Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now